Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its chief executive officer said in an interview.Lilly’s drug, Kisunla, launched ...

NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple ...

New LEQEMBI Companion TM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an ...

Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both ...

Biogen and Eisai recently announced that Chinese regulators have accepted their Biologics License Application for a subcutaneous, at‑home injectable version of Alzheimer’s drug LEQEMBI, advancing it ...

Biogen Inc.‘s (NASDAQ: BIIB) partner Eisai Co., Ltd, on Friday filed a new drug application for Leqembi (lecanemab) seeking approval for a subcutaneous formulation (SC-AI) as a new route of ...

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

Biogen Inc. ( BIIB) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 4:30 PM EST ...

New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an ...

Investing.com -- Biogen Inc. ’s new at-home Alzheimer’s drug will provide an advantage over Eli Lilly Co. ’s competing ...